Supernus Pharmaceuticals | SUPN - Należności Handlowe





Należności Handlowe Zmiana Data
Abbott USD 10.57B 171M 2025-12
ANI Pharmaceuticals USD 281.08M 28.46M 2025-12
Aurora Cannabis CAD 48.26M 1.53M 2025-12
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Canopy Growth CAD 140.42M 113.56M 2025-12
Cara Therapeutics USD 2.24M 2.26M 2025-03
Corcept Therapeutics USD 39.07M 20.71M 2026-03
Eisai JPY 249.06B 25B 2025-12
Eli Lilly USD 21.18B 1.02B 2026-03
Novo Nordisk DKK 95.05B 2.4B 2025-12
Pacira USD 125.64M 1.57M 2026-03
Perrigo USD 612.8M 31.6M 2025-12
Pfizer USD 16.17B 332M 2026-03
Supernus Pharmaceuticals USD 182.18M 5.62M 2026-03
United Therapeutics USD 350.2M 52.5M 2025-12
Xeris Pharmaceuticals USD 51.05M 2.7M 2025-12